107 related articles for article (PubMed ID: 19239461)
1. A case of natural killer cell monoclonal expansion during efalizumab treatment in a patient with psoriasis.
Caproni M; Volpi W; Chiarini C; Antiga E; Giomi B; Fabbri P
Br J Dermatol; 2009 Apr; 160(4):896-7. PubMed ID: 19239461
[No Abstract] [Full Text] [Related]
2. Cytomegalovirus infection in a patient treated with efalizumab for psoriasis.
Miquel FJ; Colomina J; Maríi JI; Ortega C
Arch Dermatol; 2009 Aug; 145(8):961-2. PubMed ID: 19687445
[No Abstract] [Full Text] [Related]
3. Case reports: efalizumab-associated lymphoproliferative disease.
Bommakanti S; Patil A; Eshoa C; Chitambar CR
J Drugs Dermatol; 2007 Jun; 6(6):646-8. PubMed ID: 17668531
[TBL] [Abstract][Full Text] [Related]
4. T-cell clone associated with efalizumab therapy.
Lynch M; Murphy K; Slaby J; Kirby B
Clin Exp Dermatol; 2011 Jan; 36(1):99-100. PubMed ID: 20545952
[No Abstract] [Full Text] [Related]
5. Long-term treatment of plaque psoriasis with efalizumab: an Italian experience.
Costanzo A; Peris K; Talamonti M; Di Cesare A; Fargnoli MC; Botti E; Chimenti S
Br J Dermatol; 2007 Apr; 156 Suppl 2():17-23. PubMed ID: 17371319
[TBL] [Abstract][Full Text] [Related]
6. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
[TBL] [Abstract][Full Text] [Related]
7. Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice.
Puig L; Roé E; García-Navarro X; Corella F; Alomar A
Clin Exp Dermatol; 2009 Jun; 34(4):469-75. PubMed ID: 19077105
[TBL] [Abstract][Full Text] [Related]
8. Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute.
Ferrándiz C; Carrascosa JM
Br J Dermatol; 2007 Apr; 156 Suppl 2():24-9. PubMed ID: 17371320
[TBL] [Abstract][Full Text] [Related]
9. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital.
Antoniou C; Stefanaki I; Stratigos A; Avgerinou G; Stavropoulos P; Potouridou I; Polidorou D; Moustou AE; Kosmadaki M; Katsambas AD
Br J Dermatol; 2007 Apr; 156 Suppl 2():12-6. PubMed ID: 17371318
[TBL] [Abstract][Full Text] [Related]
10. Efalizumab-induced thrombocytopenia: report of relapse after re-administration.
Kiorpelidou D; Tsiouri G; Gaitanis G; Akritidis N; Bassukas ID
Clin Exp Dermatol; 2009 Dec; 34(8):e914-6. PubMed ID: 20055866
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
[TBL] [Abstract][Full Text] [Related]
12. Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome.
Driessen RJ; Berends MA; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2008 May; 158(5):1098-106. PubMed ID: 18384440
[TBL] [Abstract][Full Text] [Related]
13. Serum sickness-like reaction associated with efalizumab.
Ashraf-Benson S; Wall GC; Veach LA
Ann Pharmacother; 2009 Feb; 43(2):383-6. PubMed ID: 19193578
[TBL] [Abstract][Full Text] [Related]
14. Lymphomatoid papulosis while on efalizumab.
Leo AM; Ermolovich T
J Am Acad Dermatol; 2009 Sep; 61(3):540-1. PubMed ID: 19700027
[No Abstract] [Full Text] [Related]
15. Disseminated eruptive giant mollusca contagiosa in an adult psoriasis patient during efalizumab therapy.
Weisenseel P; Kuznetsov AV; Flaig M; Prinz JC
Dermatology; 2008; 217(1):85-6. PubMed ID: 18446030
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy.
Costanzo A; Talamonti M; Spallone G; Botti E; Chimenti MS; Papoutsaki M; Chimenti S
Dermatology; 2009; 218(2):146-50. PubMed ID: 18971577
[TBL] [Abstract][Full Text] [Related]
17. Efalizumab in the treatment of chronic plaque psoriasis: experiences from the largest psoriasis treatment centre in Denmark.
Kragballe K
Br J Dermatol; 2007 Apr; 156 Suppl 2():7-11. PubMed ID: 17371317
[TBL] [Abstract][Full Text] [Related]
18. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
[TBL] [Abstract][Full Text] [Related]
19. Efalizumab in routine use: a clinical experience.
Selenko-Gebauer N; Karlhofer F; Stingl G
Br J Dermatol; 2007 Apr; 156 Suppl 2():1-6. PubMed ID: 17371316
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus complicating biological immunosuppressive therapy in two patients with psoriasis receiving treatment with etanercept or efalizumab.
Petersen B; Lorentzen H
Acta Derm Venereol; 2008; 88(5):523-4. PubMed ID: 18779901
[No Abstract] [Full Text] [Related]
[Next] [New Search]
